Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MS Drug Prices Far Exceed Value Thresholds, Even At Current Discounts – ICER Report

Executive Summary

List pricing for Biogen’s Tecfidera and Novartis’ Gilenya would need to be discounted 47% and 50%, respectively, for them to be considered good values, ICER concludes in a new report. But three products come in under ICER's thresholds.

You may also be interested in...



Gilenya Patent Upheld, But Who's The Biggest Winner – Novartis or Celgene?

A composition of matter patent for the Novartis MS drug Gilenya expires in 2019, but a recent inter partes review decision upheld a dosing patent that doesn't expire until 2027. However, analysts also touted the victory as a big win for Celgene and its competing S1P modulator ozanimod.

Ocrevus Launching Quickly Even After Manufacturing Worries Delayed US Approval

Genentech’s ocrelizumab, a CD20-directed antibody, becomes first US-approved treatment for primary progressive multiple sclerosis and is also indicated for relapsing disease. Labeling includes warnings about infusion reactions, infections and malignancy but lacks a boxed warning or REMS.

Teva Undertaking Strategic Review As It Searches For New CEO

Execs were pushed for details during earnings call but offer minimal clarity. Teva is sticking by the guidance issued before its loss in Copaxone patent case, and is upping investment in promoting the brand while the decision is appealed.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS119958

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel